It suggested that dual inhibition of Nrf2 anti-oxidant signaling and HER2-AKT/ERK1/2 signaling is crucial for the anti-tumor effect of HER2-targeted therapeutics in HER2-overexpressed tumors. The gene discussed is ERBB2; the disease is neoplasm.